<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276392</url>
  </required_header>
  <id_info>
    <org_study_id>01-AHTSDKM</org_study_id>
    <nct_id>NCT01276392</nct_id>
  </id_info>
  <brief_title>Anticoagulation and Activation - Comparison in Continuous Renal Replacement Therapy</brief_title>
  <official_title>Platelet Function, Whole Blood Coagulation and Fibrinolysis During Continuous Renal Replacement Therapy - a Comparison of Citrate and Heparin Anticoagulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinik für Anästhesiologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Actual clinical practice predominantly makes use of heparin (systemically) or citrate
      regionally as anticoagulation in the extracorporeal circulation for renal replacement
      therapy. We aim to find out if different anticoagulation strategies may lead to different
      levels of platelet activation and whole blood coagulation. Regarding coagulation activation,
      it remains uncertain if there is an advantage for one of these methods. However, it is of
      major interest to minimize the risk of any additional clotting activation via extracorporeal
      circulation in these usually critically ill patients.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    A main person involved left the site
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Filter life time of continuous renal replacement therapy</measure>
    <time_frame>Individual time point, standardized</time_frame>
    <description>Filter life time measured in hours of duration of continuos renal replacement therapy, filter life time end, when system clotts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activation of coagulation</measure>
    <time_frame>beginning of hemodialysis, 1,2,4,12,24,28,72 hours after start of hemodialysis</time_frame>
    <description>blood samples for multiplate, rotem and systemic coagulation paramters</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Kidney Replacement Disorder</condition>
  <arm_group>
    <arm_group_label>Heparin</arm_group_label>
    <description>10 Patients undergoing continuous renal replacement therapy using heparin for providing anticoagulation. Blood samples taken at 8 predefined timepoints.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CiCa</arm_group_label>
    <description>10 Patients undergoing continuous renal replacement therapy using citrate for providing anticoagulation. Blood samples taken at 8 predefined timepoints.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Critical ill patients with acute renal failure and the need of continuous renal replacement
        therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years, acute renal failure with need for continuous veno-venous renal
             replacement therapy

        Exclusion Criteria:

          -  Age &lt; 18 years, pregnancy, contraindications for one of the two anticoagulation
             methods, missing informed consent or disagreement in the progress of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Detlev Kindgen-Milles, Professor,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, University Hospital Duesseldorf, Heinrich Heine University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Interdisciplinary Operative Intensive Care Unit, University Hospital Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <state>NRW</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Schaefer RM, Barenbrock M, Teschner M, Bahner U. [Extracorporeal renal replacement therapies in acute renal failure]. Med Klin (Munich). 2000 May 15;95(5):273-8. Review. German.</citation>
    <PMID>10850066</PMID>
  </reference>
  <reference>
    <citation>Toft P, Gilsaa T. [Acute renal failure in critically ill patients]. Ugeskr Laeger. 2007 Feb 19;169(8):692-5. Danish.</citation>
    <PMID>17313917</PMID>
  </reference>
  <reference>
    <citation>Davenport A. The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuit. Am J Kidney Dis. 1997 Nov;30(5 Suppl 4):S20-7. Review.</citation>
    <PMID>9372975</PMID>
  </reference>
  <reference>
    <citation>Bouman CS, de Pont AC, Meijers JC, Bakhtiari K, Roem D, Zeerleder S, Wolbink G, Korevaar JC, Levi M, de Jonge E. The effects of continuous venovenous hemofiltration on coagulation activation. Crit Care. 2006;10(5):R150.</citation>
    <PMID>17069648</PMID>
  </reference>
  <reference>
    <citation>Sabovic M, Salobir B, Preloznik Zupan I, Bratina P, Bojec V, Buturovic Ponikvar J. The influence of the haemodialysis procedure on platelets, coagulation and fibrinolysis. Pathophysiol Haemost Thromb. 2005;34(6):274-8.</citation>
    <PMID>16772739</PMID>
  </reference>
  <reference>
    <citation>Lang T, von Depka M. [Possibilities and limitations of thrombelastometry/-graphy]. Hamostaseologie. 2006 Aug;26(3 Suppl 1):S20-9. German.</citation>
    <PMID>16953288</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2011</study_first_submitted>
  <study_first_submitted_qc>January 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2011</study_first_posted>
  <last_update_submitted>August 19, 2015</last_update_submitted>
  <last_update_submitted_qc>August 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik für Anästhesiologie</investigator_full_name>
    <investigator_title>Leiter Interdisziplinäre Operative Intensivstation ZOM-I</investigator_title>
  </responsible_party>
  <keyword>regional and systemical anticoagulation</keyword>
  <keyword>continuous renal replacement therapy</keyword>
  <keyword>multiplate</keyword>
  <keyword>rotational thrombelastometry</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

